430 results on '"Zagouri, F"'
Search Results
2. Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix
3. Detection of hotspot PIK3CA mutations in primary tumors and plasma-cfDNA of breast cancer patients using a novel highly sensitive CE-IVD KIT
4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
5. Immune checkpoint inhibitor administration during pregnancy: a case series
6. How we treat endocrine complications of immune checkpoint inhibitors
7. The effect of anthracycline-based chemotherapy on endothelial function and arterial stiffness in breast cancer patients
8. Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience
9. Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
10. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
11. ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
12. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
13. Paving the way for changing perceptions in breast surgery: a systematic literature review focused on oncological and aesthetic outcomes of oncoplastic surgery for breast cancer
14. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
15. 79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs
16. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
17. Axitinib as a third or further line of treatment in renal cancer: a single institution experience
18. OVARIAN CANCER TREATMENT IN THE ELDERLY: EP905
19. NEOADJUVANT CHEMOTHERAPY FOR NEWLY DIAGNOSED OVARIAN CANCER: A SINGLE CENTER EXPERIENCE: EP881
20. 77P The impact of COVID-19 on gynecological cancer diagnoses in Greece
21. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
22. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG)
23. Cell-free DNA concentration in patients with different molecular subtypes of breast cancer
24. VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis
25. A Phase 3 Study of Pembrolizumab (Pembro) + Concurrent Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC): Safety Findings
26. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
27. 709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
28. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
29. 27P Association between CD8+ tumor infiltrating lymphocytes and the clinical outcome of patients with operable breast cancer treated with adjuvant dose-dense chemotherapy: A 10-year follow up report of a Hellenic Cooperative Oncology Group observational study
30. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
31. 'The emerging role of capivasertib in breast cancer'
32. Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
33. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
34. Adjuvant Treatment of Elderly Breast Cancer Patients: Offer the Best Chances of Cure
35. High-throughput Proteomic Profiling of Male Breast Cancer Tissue
36. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
37. Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review
38. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial
39. Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors
40. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
41. 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
42. P154 - Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience
43. Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study
44. Safety outcomes from monarchE: phase 3 study of abemaciclib combined with endocrine therapy (ET) for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer (EBC)
45. Trastuzumab administration during pregnancy: un update
46. How we treat endocrine complications of immune checkpoint inhibitors
47. Androgen receptor and PIM1 expression in tumor tissue of patients with triple-negative breast cancer
48. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
49. Aromatase and CDK4/6 inhibitor-induced musculoskeletal symptoms: A systematic review
50. Management of the elderly patients with high-grade serous ovarian cancer in the real-world setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.